NCT07507318 2026-04-02
DEL-MRD-CHID
Fudan University
Phase 2 Not yet recruiting
Clinical Trials
20 trialsNCT07502872 2026-03-31
TPG
Brown University
Phase 2 Not yet recruiting
NCT07494565 2026-03-27
Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06594939 2026-02-04
Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma
Medical College of Wisconsin
Phase 2 Not yet recruiting
NCT07365306 2026-01-26
Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT07197307 2025-09-29
CLEAR
Universität Münster
Phase 2 Not yet recruiting
NCT06665217 2025-08-14
G-Pola-ZLP in Diffuse Large B-Cell Lymphoma
Navy General Hospital, Beijing
Phase 2 Not yet recruiting
NCT07012980 2025-06-10
Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT06921044 2025-04-10
A Study of R-mini-MCOP in the Treatment of Elderly, Previously Untreated DLBCL
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT06867536 2025-03-18
GLOHRT-01
Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT06778902 2025-01-16
Dragon
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Not yet recruiting
NCT06748521 2024-12-27
Dynamic CtDNA-guided Targeted Therapy in DLBCL
Ruijin Hospital
Phase 2 Not yet recruiting
NCT06669143 2024-11-01
Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission
Ruijin Hospital
Phase 2 Not yet recruiting
NCT06652139 2024-10-22
Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive
Ruijin Hospital
Phase 2 Not yet recruiting
NCT06594432 2024-09-19
Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT06516978 2024-07-24
A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT06441097 2024-06-04
Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
Ruijin Hospital
Phase 2 Not yet recruiting
NCT06062641 2023-11-07
Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL
Ruijin Hospital
Phase 2 Not yet recruiting
NCT05596097 2022-10-27
Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission
LanZhou University
Phase 2 Not yet recruiting
NCT05280626 2022-03-15
First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2 Not yet recruiting